Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19 CAR-NK and 7x19 CAR-T in R/R B-cell Lymphoma
NCT06464861Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR-NK019 and 7x19 CAR-T in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), primary mediastinal large B-cell lymphoma (PMBCL) and 1 more, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of dose limiting toxicity at 28 days. Started Jun 2024; status: recruiting.
02
Drugs
CAR-NK0197x19 CAR-T
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06464861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464861.